Since repotrectinib shows selectivity for ALK, we decided to investigate repotrectinib in a neuroblastoma setting focusing on its effects on ALK, including ALK gain of function mutations relevant in neuroblastoma. The gene discussed is ALK; the disease is neuroblastoma.